Nathan W. Cummins, M.D.

Nathan W. Cummins, M.D., of Mayo Clinic in Rochester, Minn., wants to revolutionize the way human immunodeficiency virus (HIV) medicine specialists and HIV-infected patients select their lifesaving medications, minimizing the significant side effects that frequently go along with wonder drugs.

Dr. Cummins is investigating whether testing patients' genes and selecting antiviral medications based on those results will decrease medication side effects, improve medication tolerability and improve outcomes in HIV-infected patients.

In his research, Dr. Cummins uses pharmacogenomics, which analyzes how genetic makeup affects drug response. Mayo Clinic is an international leader in pharmacogenomics and HIV medicine. Mayo's HIV Clinic provides patient care through an integrated, multidisciplinary team of physicians, scientists and allied health professionals.

"The unique expertise provided by the Mayo HIV Clinic produces an exceptional track record for moving pharmacogenomics, a type of personalized medicine, into routine clinical practice," says Dr. Cummins. "The exceptionally skillful, motivated and caring professionals at the HIV Clinic are dedicated and focused on improving the lives of our patients."

Dr. Cummins says being a KL2 scholar provides a unique opportunity to receive dedicated training in translational research methodologies, mentorship from leaders in translational medicine, and the time and resources to conduct multidisciplinary, transformative research.

"Moving scientific discoveries from the laboratory to the Mayo HIV Clinic, where the discoveries are most needed, is what inspires me to do clinical and translational research," says Dr. Cummins.


  • May 3, 2013
  • PRO799871